Novacyt Initiation of Coverage: Through the rapid commercialisation of a COVID-19 test, Novacyt has transformed its financial position. Demand for the Group's COVID-19 test and other COVID-19 reagents are expected to make up the majority of revenue generated until FY22E, whereupon the Group is looking to drive long-term growth across its business via the development of high-margin clinical diagnostics and establish itself as a leader in infectious disease testing.
21 Oct 2020
SP Angel Healthcare Conditions- Novacyt (NCYT.L): Initiation of Research
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
SP Angel Healthcare Conditions- Novacyt (NCYT.L): Initiation of Research
Novacyt SAS (NCYT:LON) | 71.5 2.1 4.4% | Mkt Cap: 50.5m
- Published:
21 Oct 2020 -
Author:
Vadim Alexandre | Liam Gascoigne-Cohen -
Pages:
32
Novacyt Initiation of Coverage: Through the rapid commercialisation of a COVID-19 test, Novacyt has transformed its financial position. Demand for the Group's COVID-19 test and other COVID-19 reagents are expected to make up the majority of revenue generated until FY22E, whereupon the Group is looking to drive long-term growth across its business via the development of high-margin clinical diagnostics and establish itself as a leader in infectious disease testing.